Done-To The Moon - Tiger Brokers Online Investing Community - To The Moon

1
Comment
Favorite

Kelvinneo
2021-09-09

Done

The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week

Biotech stocks extended their gains in the week ending Sept. 3, partly aided by the broader market strength. The news flow was fairly light ahead of the Labor Day holiday weekend.

The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

1

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":883080948,"tweetId":"883080948","gmtCreate":1631188896284,"gmtModify":1676530491306,"author":{"id":3576527829922352,"idStr":"3576527829922352","authorId":3576527829922352,"authorIdStr":"3576527829922352","name":"Kelvinneo","avatar":"https://static.tigerbbs.com/02f9dc9fba8b950702638da01ab252b8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.14","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":25,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Done</p></body></html>","htmlText":"<html><head></head><body><p>Done</p></body></html>","text":"Done","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/883080948","repostId":2165802495,"repostType":2,"repost":{"id":"2165802495","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1630862048,"share":"https://ttm.financial/m/news/2165802495?lang=en_US&edition=fundamental","pubTime":"2021-09-06 01:14","market":"hk","language":"en","title":"The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2165802495","media":"Benzinga","summary":"Biotech stocks extended their gains in the week ending Sept. 3, partly aided by the broader market strength. The news flow was fairly light ahead of the Labor Day holiday weekend.","content":"<html><body><p>Biotech stocks extended their gains in the week ending Sept. 3, partly aided by the broader market strength. The news flow was fairly light ahead of the Labor Day holiday weekend.</p>\n<p>Clinical readouts swung stocks wildly during the week. <strong>Forte Biosciences, Inc. </strong>(NASDAQ:FBRX)  plunged over 80% in reaction to its announcement that the Phase 2 clinical study of its investigational asset FB-401 for the treatment of atopic dermatitis failed to meet its primary endpoint with statistical significance.</p>\n<p>On the regulatory front, <strong><a href=\"https://laohu8.com/S/IMPL\">Impel NeuroPharma, Inc.</a> </strong>(NASDAQ:IMPL) received the Food and Drug Administration's approval for Trudhesa, its lead candidate, for the treatment of acute migraine. On a not-so-positive note, a Wall Street Journal report suggested that the FDA is in no hurry to approve <strong>Pfizer, Inc. </strong>(NYSE:PFE)-<strong><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> </strong>(NASDAQ:BNTX)'s COVID-19 vaccine booster shot.</p>\n<p>Here are the key catalytic events for the unfolding week:</p>\n<h3>Conferences</h3>\n<ul>\n<li>International Liver Conference Association, or ILCA, Annual Conference (virtual): Sept. 2-5</li>\n<li>European Respiratory Society, or ERS, International Conference 2021 (virtual): Sept. 5-8</li>\n<li>Goldman Sachs Eleventh Annual Biotech Symposium: Sept. 7-10</li>\n<li>Citi's 16th Annual BioPharma Conference (virtual): Sept. 8-10</li>\n<li>2021 Wells Fargo Virtual Healthcare Conference (virtual): Sept. 9-10</li>\n<li><a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> 19th Annual Global Healthcare Conference (virtual): Sept. 9-15</li>\n<li>American Urological Association, AUA, Conference (virtual): Sept. 10-13</li>\n<li>Heart Failure Society of America, or HFSA, Annual Scientific Meeting (both virtual and in-person, hybrid format): Sept. 10-13</li>\n<li>International Association of the Study of Lung Cancer, or IASLC, 2021 World Conference on Lung Cancer (virtual): Sept. 11-14</li>\n</ul>\n<p><em>Related Link:  Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates </em></p>\n<h3>Clinical Readouts/Presentations</h3>\n<p><a href=\"https://laohu8.com/S/PLRX\">Pliant Therapeutics, Inc.</a> (NASDAQ:PLRX) will release Tuesday, Sept. 7, interim clinical data from an ongoing Phase 2a positron emission tomography imaging trial of PLN-74809 in patients with idiopathic pulmonary fibrosis.</p>\n<p><strong>INmune Bio, Inc. </strong>(NASDAQ:INMB) is due to present additional Phase 1b data on XPro, its selective DN-TNF inhibitor candidate for the treatment of Alzheimer's disease, treatment resistant depression, and other neurological diseases where neuroinflammation is implicated. The presentation is scheduled for Tuesday, Sept. 7, at 4:30 pm.</p>\n<p><strong><a href=\"https://laohu8.com/S/VNVLF\">Valneva SE</a> </strong>(NASDAQ:VALN) said, at the Goldman Sachs Biotech Symposium, it will present an update on its late stage vaccine candidate VLA-15 against Lyme disease. The company is partnering with Pfizer for this program. Valneva will also present updates on its two more late-stage vaccine candidates - VLA2001 against COVID-19 and VLA 1553 against chikungunya. VLA2001 is being evaluated in combination with <strong> Dynavax Technologies Corporation </strong>(NASDAQ:DVAX)'s vaccine adjuvant and alum. The presentations are scheduled for Tuesday, Sept. 7.</p>\n<p><strong><a href=\"https://laohu8.com/S/CRDF\">Cardiff Oncology, Inc.</a> </strong>(NASDAQ:CRDF) will present new data from its Phase 1b/2 clinical trial evaluating onvansertib in combination with standard-of-care FOLFIRI/<strong>Bristol-Mysrs Squibb Company </strong>(NYSE:BMY)'s Avastin in KRAS-mutated metastatic colorectal cancer. The presentation is organized as a virtual KOL event for analysts, investors, and the scientific community on Wednesday, Sept. 8, between 4 pm and 5 pm.</p>\n<p><strong><a href=\"https://laohu8.com/S/IBRX\">ImmunityBio, Inc.</a> </strong>(NASDAQ:IBRX) will present at the AUA conference Phase 2/3 clinical results of IL-15 Superagonist N-803 with BCG in BCG-unresponsive bladder cancer. The presentation is scheduled for Friday, Sept. 10.</p>\n<p><strong>Mersana Therapeutics, Inc. </strong>(NASDAQ:MRSN) will host a webcast to discuss progress of its clinical development strategy for upifitamab rilsodotin and report updated interim data from the ovarian cancer expansion cohort of the UpRi Phase 1 study. The webcast is scheduled for Friday, Sept. 10, at 8 am.</p>\n<h3>Earnings</h3>\n<ul>\n<li><strong>Centogene N.V. </strong>(NASDAQ:CNTG) (Tuesday, before the market open)</li>\n<li><strong>Affimed N.V. </strong>(NASDAQ:AFMD) (Wednesday, before the market open)</li>\n<li><strong><a href=\"https://laohu8.com/S/TRIB\">Trinity Biotech plc</a> </strong>(NASDAQ:TRIB) (Thursday, before the market open)</li>\n</ul>\n<h3>IPOs</h3>\n<p><strong>IPO Quiet Period Expiry </strong></p>\n<p><strong><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> </strong>(NASDAQ:DRMA)</p>\n<p><em>Related Link: Why Cassava Sciences Stock Investors Are Pulling Back </em></p>\n</body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-09-06 01:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Biotech stocks extended their gains in the week ending Sept. 3, partly aided by the broader market strength. The news flow was fairly light ahead of the Labor Day holiday weekend.</p>\n<p>Clinical readouts swung stocks wildly during the week. <strong>Forte Biosciences, Inc. </strong>(NASDAQ:FBRX)  plunged over 80% in reaction to its announcement that the Phase 2 clinical study of its investigational asset FB-401 for the treatment of atopic dermatitis failed to meet its primary endpoint with statistical significance.</p>\n<p>On the regulatory front, <strong><a href=\"https://laohu8.com/S/IMPL\">Impel NeuroPharma, Inc.</a> </strong>(NASDAQ:IMPL) received the Food and Drug Administration's approval for Trudhesa, its lead candidate, for the treatment of acute migraine. On a not-so-positive note, a Wall Street Journal report suggested that the FDA is in no hurry to approve <strong>Pfizer, Inc. </strong>(NYSE:PFE)-<strong><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> </strong>(NASDAQ:BNTX)'s COVID-19 vaccine booster shot.</p>\n<p>Here are the key catalytic events for the unfolding week:</p>\n<h3>Conferences</h3>\n<ul>\n<li>International Liver Conference Association, or ILCA, Annual Conference (virtual): Sept. 2-5</li>\n<li>European Respiratory Society, or ERS, International Conference 2021 (virtual): Sept. 5-8</li>\n<li>Goldman Sachs Eleventh Annual Biotech Symposium: Sept. 7-10</li>\n<li>Citi's 16th Annual BioPharma Conference (virtual): Sept. 8-10</li>\n<li>2021 Wells Fargo Virtual Healthcare Conference (virtual): Sept. 9-10</li>\n<li><a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> 19th Annual Global Healthcare Conference (virtual): Sept. 9-15</li>\n<li>American Urological Association, AUA, Conference (virtual): Sept. 10-13</li>\n<li>Heart Failure Society of America, or HFSA, Annual Scientific Meeting (both virtual and in-person, hybrid format): Sept. 10-13</li>\n<li>International Association of the Study of Lung Cancer, or IASLC, 2021 World Conference on Lung Cancer (virtual): Sept. 11-14</li>\n</ul>\n<p><em>Related Link:  Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates </em></p>\n<h3>Clinical Readouts/Presentations</h3>\n<p><a href=\"https://laohu8.com/S/PLRX\">Pliant Therapeutics, Inc.</a> (NASDAQ:PLRX) will release Tuesday, Sept. 7, interim clinical data from an ongoing Phase 2a positron emission tomography imaging trial of PLN-74809 in patients with idiopathic pulmonary fibrosis.</p>\n<p><strong>INmune Bio, Inc. </strong>(NASDAQ:INMB) is due to present additional Phase 1b data on XPro, its selective DN-TNF inhibitor candidate for the treatment of Alzheimer's disease, treatment resistant depression, and other neurological diseases where neuroinflammation is implicated. The presentation is scheduled for Tuesday, Sept. 7, at 4:30 pm.</p>\n<p><strong><a href=\"https://laohu8.com/S/VNVLF\">Valneva SE</a> </strong>(NASDAQ:VALN) said, at the Goldman Sachs Biotech Symposium, it will present an update on its late stage vaccine candidate VLA-15 against Lyme disease. The company is partnering with Pfizer for this program. Valneva will also present updates on its two more late-stage vaccine candidates - VLA2001 against COVID-19 and VLA 1553 against chikungunya. VLA2001 is being evaluated in combination with <strong> Dynavax Technologies Corporation </strong>(NASDAQ:DVAX)'s vaccine adjuvant and alum. The presentations are scheduled for Tuesday, Sept. 7.</p>\n<p><strong><a href=\"https://laohu8.com/S/CRDF\">Cardiff Oncology, Inc.</a> </strong>(NASDAQ:CRDF) will present new data from its Phase 1b/2 clinical trial evaluating onvansertib in combination with standard-of-care FOLFIRI/<strong>Bristol-Mysrs Squibb Company </strong>(NYSE:BMY)'s Avastin in KRAS-mutated metastatic colorectal cancer. The presentation is organized as a virtual KOL event for analysts, investors, and the scientific community on Wednesday, Sept. 8, between 4 pm and 5 pm.</p>\n<p><strong><a href=\"https://laohu8.com/S/IBRX\">ImmunityBio, Inc.</a> </strong>(NASDAQ:IBRX) will present at the AUA conference Phase 2/3 clinical results of IL-15 Superagonist N-803 with BCG in BCG-unresponsive bladder cancer. The presentation is scheduled for Friday, Sept. 10.</p>\n<p><strong>Mersana Therapeutics, Inc. </strong>(NASDAQ:MRSN) will host a webcast to discuss progress of its clinical development strategy for upifitamab rilsodotin and report updated interim data from the ovarian cancer expansion cohort of the UpRi Phase 1 study. The webcast is scheduled for Friday, Sept. 10, at 8 am.</p>\n<h3>Earnings</h3>\n<ul>\n<li><strong>Centogene N.V. </strong>(NASDAQ:CNTG) (Tuesday, before the market open)</li>\n<li><strong>Affimed N.V. </strong>(NASDAQ:AFMD) (Wednesday, before the market open)</li>\n<li><strong><a href=\"https://laohu8.com/S/TRIB\">Trinity Biotech plc</a> </strong>(NASDAQ:TRIB) (Thursday, before the market open)</li>\n</ul>\n<h3>IPOs</h3>\n<p><strong>IPO Quiet Period Expiry </strong></p>\n<p><strong><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> </strong>(NASDAQ:DRMA)</p>\n<p><em>Related Link: Why Cassava Sciences Stock Investors Are Pulling Back </em></p>\n</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRIB":"Trinity Biotech plc","CRDF":"Cardiff Oncology, Inc.","DRMA":"Dermata Therapeutics Inc","BMY":"施贵宝","PFE":"辉瑞","DVAX":"德纳维制药","IBB":"生物科技指数ETF-iShares Nasdaq","AFMD":"Affimed NV","TERN":"Terns Pharmaceuticals, Inc.","MRSN":"Mersana Therapeutics Inc.","IMPL":"Impel NeuroPharma, Inc.","INMB":"INmune Bio Inc","BNTX":"BioNTech SE","PLRX":"Pliant Therapeutics, Inc.","VALN":"Valneva SE","CRCT":"Cricut, Inc.","IBRX":"ImmunityBio, Inc.","CNTG":"Centogene B.V.","FBRX":"Forte BioSciences Inc"},"source_url":"https://www.benzinga.com/general/biotech/21/09/22811453/the-week-ahead-in-biotech-sept-5-11-focus-on-conferences-and-clinical-readouts-in-another-quiet-w","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2165802495","content_text":"Biotech stocks extended their gains in the week ending Sept. 3, partly aided by the broader market strength. The news flow was fairly light ahead of the Labor Day holiday weekend.\nClinical readouts swung stocks wildly during the week. Forte Biosciences, Inc. (NASDAQ:FBRX)  plunged over 80% in reaction to its announcement that the Phase 2 clinical study of its investigational asset FB-401 for the treatment of atopic dermatitis failed to meet its primary endpoint with statistical significance.\nOn the regulatory front, Impel NeuroPharma, Inc. (NASDAQ:IMPL) received the Food and Drug Administration's approval for Trudhesa, its lead candidate, for the treatment of acute migraine. On a not-so-positive note, a Wall Street Journal report suggested that the FDA is in no hurry to approve Pfizer, Inc. (NYSE:PFE)-BioNTech SE (NASDAQ:BNTX)'s COVID-19 vaccine booster shot.\nHere are the key catalytic events for the unfolding week:\nConferences\n\nInternational Liver Conference Association, or ILCA, Annual Conference (virtual): Sept. 2-5\nEuropean Respiratory Society, or ERS, International Conference 2021 (virtual): Sept. 5-8\nGoldman Sachs Eleventh Annual Biotech Symposium: Sept. 7-10\nCiti's 16th Annual BioPharma Conference (virtual): Sept. 8-10\n2021 Wells Fargo Virtual Healthcare Conference (virtual): Sept. 9-10\nMorgan Stanley 19th Annual Global Healthcare Conference (virtual): Sept. 9-15\nAmerican Urological Association, AUA, Conference (virtual): Sept. 10-13\nHeart Failure Society of America, or HFSA, Annual Scientific Meeting (both virtual and in-person, hybrid format): Sept. 10-13\nInternational Association of the Study of Lung Cancer, or IASLC, 2021 World Conference on Lung Cancer (virtual): Sept. 11-14\n\nRelated Link:  Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates \nClinical Readouts/Presentations\nPliant Therapeutics, Inc. (NASDAQ:PLRX) will release Tuesday, Sept. 7, interim clinical data from an ongoing Phase 2a positron emission tomography imaging trial of PLN-74809 in patients with idiopathic pulmonary fibrosis.\nINmune Bio, Inc. (NASDAQ:INMB) is due to present additional Phase 1b data on XPro, its selective DN-TNF inhibitor candidate for the treatment of Alzheimer's disease, treatment resistant depression, and other neurological diseases where neuroinflammation is implicated. The presentation is scheduled for Tuesday, Sept. 7, at 4:30 pm.\nValneva SE (NASDAQ:VALN) said, at the Goldman Sachs Biotech Symposium, it will present an update on its late stage vaccine candidate VLA-15 against Lyme disease. The company is partnering with Pfizer for this program. Valneva will also present updates on its two more late-stage vaccine candidates - VLA2001 against COVID-19 and VLA 1553 against chikungunya. VLA2001 is being evaluated in combination with  Dynavax Technologies Corporation (NASDAQ:DVAX)'s vaccine adjuvant and alum. The presentations are scheduled for Tuesday, Sept. 7.\nCardiff Oncology, Inc. (NASDAQ:CRDF) will present new data from its Phase 1b/2 clinical trial evaluating onvansertib in combination with standard-of-care FOLFIRI/Bristol-Mysrs Squibb Company (NYSE:BMY)'s Avastin in KRAS-mutated metastatic colorectal cancer. The presentation is organized as a virtual KOL event for analysts, investors, and the scientific community on Wednesday, Sept. 8, between 4 pm and 5 pm.\nImmunityBio, Inc. (NASDAQ:IBRX) will present at the AUA conference Phase 2/3 clinical results of IL-15 Superagonist N-803 with BCG in BCG-unresponsive bladder cancer. The presentation is scheduled for Friday, Sept. 10.\nMersana Therapeutics, Inc. (NASDAQ:MRSN) will host a webcast to discuss progress of its clinical development strategy for upifitamab rilsodotin and report updated interim data from the ovarian cancer expansion cohort of the UpRi Phase 1 study. The webcast is scheduled for Friday, Sept. 10, at 8 am.\nEarnings\n\nCentogene N.V. (NASDAQ:CNTG) (Tuesday, before the market open)\nAffimed N.V. (NASDAQ:AFMD) (Wednesday, before the market open)\nTrinity Biotech plc (NASDAQ:TRIB) (Thursday, before the market open)\n\nIPOs\nIPO Quiet Period Expiry \nDermata Therapeutics, Inc. (NASDAQ:DRMA)\nRelated Link: Why Cassava Sciences Stock Investors Are Pulling Back","news_type":1,"symbols_score_info":{"CNTG":0.9,"FBRX":0.9,"IBRX":0.9,"PLRX":0.9,"BMY":0.9,"IMPL":0.9,"MRSN":0.9,"CRDF":0.9,"INMB":0.9,"VALN":0.9,"AFMD":0.9,"PFE":0.9,"IBB":0.9,"DRMA":0.9,"CRCT":0.9,"TERN":0.9,"DVAX":0.9,"TRIB":0.9,"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":2030,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}